Sally C. Pipes
Commentary
Read the latest on Senator Sanders' fight against major pharmaceutical firms
Sanders Won’t Let Facts Get In Way of a Good Pharma Shaming
Vermont Senator Bernie Sanders called the CEOs of several major pharmaceutical firms to testify earlier this month before the Senate Health, Education, Labor and Pensions Committee, where he serves as chairman. The hearing’s official purpose was to discuss prescription drug pricing. But it mainly offered Sanders a forum to castigate the pharmaceutical ...
Commentary
Why weakening of intellectual property rules is a threat to California
This week, members of the World Trade Organization have convened half a world away in Abu Dhabi. But a proposal on the agenda could have profound consequences for us here in California. Representatives of the World Trade Organization’s 164 member nations will discuss whether to waive patent protections on COVID-19 ...
Commentary
Medical debt isn’t a crisis
The Left has long insisted that medical debt is a national crisis and that the federal government needs to do something about it. They appear to have new ammunition in the form of an analysis published this month by the Peterson Center on Healthcare and KFF. Nearly one in 12 adults — 20.4 million people — had medical debt in 2021, ...
Commentary
Golden State May Learn Single-Payer Mania Has Hefty Price
The California legislature will soon consider yet another bid to launch a government takeover of the state’s health insurance system. Known as the California Guaranteed Health Care for All Act, AB 2200 seeks to ban private health insurance and enroll all state residents — including those currently covered by Medicare and Medi-Cal, ...
Commentary
President Biden Is His Own Worst Enemy In The War On Cancer
Cancer is becoming more common. This year, the number of new cancer cases among Americans is projected to exceed 2 million for the first time ever, according to a paper published last month by the American Cancer Society. The disease is also afflicting people earlier in their lives. Cancer diagnosis rates for ...
Commentary
Trump vs. Obamacare — More Market Efficiency, Less Government Bureaucracy
Donald Trump is continuing to make his case for an overhaul of the Affordable Care Act. “We’re going to fight for much better health care than Obamacare. Obamacare is a catastrophe,” he said just before his victory in the Iowa Caucuses in January. He’s right to put healthcare reform at ...
Commentary
Loss of Medicaid isn’t a crisis. It’s a chance to make coverage better, cheaper
More than 16 million Americans have lost Medicaid coverage in recent months, according to data from the Kaiser Family Foundation. Two million Texans have rolled off Medicaid, newly released state data show. That’s good news, despite what the Biden administration would have us believe. For decades, Medicaid has burdened taxpayers ...
Commentary
Compared To UK Physicians, US Docs Have It Made
America’s doctors are lobbying for better pay. The American Medical Association and other doctor groups are currently urging Congress to roll back a 3.37 percent cut to Medicare reimbursement rates that took effect at the beginning of the year. This quarrel over pay should disabuse U.S. doctors of any sympathy for ...
Commentary
Read about the bill in Congress that would ban the use of "quality-adjusted life years"
Congress needs to cut QALYs
The House of Representatives last week approved a bill that would ban the use of “quality-adjusted life years,” or QALYs, as well as other measures for determining the purported value of a medical intervention, in all federal health programs. Now the Senate will consider the measure. QALYs should have no place in federal decision-making about whether ...
Commentary
Read the latest on Medicare's prescription drug price-setting scheme
Can Constitution Save Us from Drug Price Controls?
AstraZeneca made its case against Medicare’s prescription drug price-setting scheme before a federal judge in Delaware last week. It’s one of several drugmakers challenging the program on constitutional grounds, among them Johnson & Johnson, Merck and Bristol Myers Squibb. Defenders of the price control plan have portrayed these cases as the machinations of money-grubbing ...
Read the latest on Senator Sanders' fight against major pharmaceutical firms
Sanders Won’t Let Facts Get In Way of a Good Pharma Shaming
Vermont Senator Bernie Sanders called the CEOs of several major pharmaceutical firms to testify earlier this month before the Senate Health, Education, Labor and Pensions Committee, where he serves as chairman. The hearing’s official purpose was to discuss prescription drug pricing. But it mainly offered Sanders a forum to castigate the pharmaceutical ...
Why weakening of intellectual property rules is a threat to California
This week, members of the World Trade Organization have convened half a world away in Abu Dhabi. But a proposal on the agenda could have profound consequences for us here in California. Representatives of the World Trade Organization’s 164 member nations will discuss whether to waive patent protections on COVID-19 ...
Medical debt isn’t a crisis
The Left has long insisted that medical debt is a national crisis and that the federal government needs to do something about it. They appear to have new ammunition in the form of an analysis published this month by the Peterson Center on Healthcare and KFF. Nearly one in 12 adults — 20.4 million people — had medical debt in 2021, ...
Golden State May Learn Single-Payer Mania Has Hefty Price
The California legislature will soon consider yet another bid to launch a government takeover of the state’s health insurance system. Known as the California Guaranteed Health Care for All Act, AB 2200 seeks to ban private health insurance and enroll all state residents — including those currently covered by Medicare and Medi-Cal, ...
President Biden Is His Own Worst Enemy In The War On Cancer
Cancer is becoming more common. This year, the number of new cancer cases among Americans is projected to exceed 2 million for the first time ever, according to a paper published last month by the American Cancer Society. The disease is also afflicting people earlier in their lives. Cancer diagnosis rates for ...
Trump vs. Obamacare — More Market Efficiency, Less Government Bureaucracy
Donald Trump is continuing to make his case for an overhaul of the Affordable Care Act. “We’re going to fight for much better health care than Obamacare. Obamacare is a catastrophe,” he said just before his victory in the Iowa Caucuses in January. He’s right to put healthcare reform at ...
Loss of Medicaid isn’t a crisis. It’s a chance to make coverage better, cheaper
More than 16 million Americans have lost Medicaid coverage in recent months, according to data from the Kaiser Family Foundation. Two million Texans have rolled off Medicaid, newly released state data show. That’s good news, despite what the Biden administration would have us believe. For decades, Medicaid has burdened taxpayers ...
Compared To UK Physicians, US Docs Have It Made
America’s doctors are lobbying for better pay. The American Medical Association and other doctor groups are currently urging Congress to roll back a 3.37 percent cut to Medicare reimbursement rates that took effect at the beginning of the year. This quarrel over pay should disabuse U.S. doctors of any sympathy for ...
Read about the bill in Congress that would ban the use of "quality-adjusted life years"
Congress needs to cut QALYs
The House of Representatives last week approved a bill that would ban the use of “quality-adjusted life years,” or QALYs, as well as other measures for determining the purported value of a medical intervention, in all federal health programs. Now the Senate will consider the measure. QALYs should have no place in federal decision-making about whether ...
Read the latest on Medicare's prescription drug price-setting scheme
Can Constitution Save Us from Drug Price Controls?
AstraZeneca made its case against Medicare’s prescription drug price-setting scheme before a federal judge in Delaware last week. It’s one of several drugmakers challenging the program on constitutional grounds, among them Johnson & Johnson, Merck and Bristol Myers Squibb. Defenders of the price control plan have portrayed these cases as the machinations of money-grubbing ...
